LFG
MDGL icon

Larson Financial Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Larson Financial Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Buy
35
+15
+75% +$7.68K ﹤0.01% 2045
2026
Q1 		$10.5K Buy
20
+3
+18% +$1.43K ﹤0.01% 2226
2025
Q4 		$9.9K Buy
17
+2
+13% +$1.02K ﹤0.01% 2123
2025
Q3 		$6.88K Buy
+15
New +$5.6K ﹤0.01% 2217
2025
Q2 		– Sell
-4
Closed -$1.32K – 3412
2025
Q1 		$1.32K Buy
+4
New +$1.31K ﹤0.01% 2302

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Larson Financial Group's MDGL Position: Q2 2026 in Review

Larson Financial Group increased its Madrigal Pharmaceuticals (MDGL) stake by 75% in Q2 2026, buying an estimated $7.68K and bringing the position to 35 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Larson Financial Group first reported a position in MDGL in Q1 2025 and has held it in 5 quarters since. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Larson Financial Group held 35 shares of Madrigal Pharmaceuticals worth $18.8K as of Q2 2026.
  • Larson Financial Group bought 15 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $7.68K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2045 holding.
  • Larson Financial Group first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.